Privacy Analytics Announces Clinical Trial Data Sharing Solution
Privacy Analytics, Inc. announced the availability of a new solution designed to enable pharmaceutical companies to share clinical trials data while protecting the privacy of the individual patients.
Privacy Analytics, Inc. announced the availability of a new solution designed to enable pharmaceutical companies to share clinical trials data while protecting the privacy of the individual patients. Privacy Analytics' Open Clinical Trials Data Review, which runs on the company's automated risk-assessment, data request, PARAT software, compares existing industry anonymization approaches and finds privacy gaps.
The new offering accelerates the ability of pharmaceutical companies to meet increasing requests for individual-level participant data and clinical study reports by academicinstitutions, patients and other third-parties.
For privacy, regulatory and medical affairs executives, Privacy Analytics now provides:
- An assessment of current in-house approaches for clinical trials data anonymization;
- Common standards and practices for evaluating and managing the risk of clinical trials data for release to third-parties; and
- Enterprise-level automation solutions for scaling clinical trial data anonymization.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
